56
- Barreiro-de-Acosta M, Lorenzo A, Dominguez-Munoz JE. Efficacy of adalimumab for
the treatment of extraintestinal manifestations of Crohn’s disease. Rev Esp Enferm Dig.
2012;104:468–72. - Peyrin-Biroulet L, Van Assche G, Gomez-Ulloa D, Garcia-Alvarez L, Lara N, Black CM, et al.
Systematic review of tumour necrosis factor antagonists in extraintestinal manifestations in
inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15:25. - Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The
first European evidence-based consensus on extra-intestinal manifestations in inflammatory
bowel disease. J Crohns Colitis. 2016;10:239–54. - Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep. 2000;2:87–8.
- Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of
inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1424–9. - Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, et al. Improvement
of arthritis and arthralgia after treatment with infliximab (Remicade) in a German pro-
spective, open-label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol.
2002;97:2688–90. - Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on
extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25:406–10. - Lofberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, et al. Adalimumab pro-
duces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results
from CARE. Inflamm Bowel Dis. 2012;18:1–9. - Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized
double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (inf-
liximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46:755–65. - Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active anky-
losing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet.
2002;359:1187–93. - Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response
to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Rheumatology. 2005;44:670–6. - van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and
safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, random-
ized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–46. - Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, et al. Infliximab in spon-
dyloarthropathy associated with Crohn’s disease: an open study on the efficacy of induc-
ing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis.
2004;63:1664–9. - Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease.
Ann Ophthalmol. 1982;14:356–60. - Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis.
Cytokine. 2006;33:231–7. - Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al.
Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–24. - Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients
with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and
etanercept. Arthritis Rheum. 2005;52:2447–51. - Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for
refractory childhood uveitis. Ophthalmology. 2006;113:860–4. e2 - Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necro-
sis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology. 2006;45:982–9. - Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
Rheumatology. 2005;44:1008–11.
D.I. Fudman and S.N. Flier